What Triggers an Infusion Reaction in Cancer Care?

Not every adverse event during an IV therapy session is a true allergy. According to Barroso et al. (2024), some reactions stem from genuine allergic immune responses that activate cells to release histamine, whereas others are non-allergic events driven by inflammatory substances called cytokines (Chung, 2008).

The likelihood of experiencing these symptoms depends heavily on the specific medicine, prior exposure, how fast the drug is infused, and individual patient traits. While certain drugs provoke issues during the initial doses, other regimens—particularly platinum-based chemotherapies—tend to trigger reactions only after repeated exposure (Barroso et al., 2024). Furthermore, data from the American Cancer Society (2024) notes that women face a higher statistical likelihood of developing these events, and individuals with past drug allergies carry an elevated risk.

Recognizing Common and Severe Symptoms

Reactions typically materialize while the medicine is running or within the first few hours afterward, though delayed responses can occasionally surface days or weeks later (American Cancer Society, 2024; Barroso et al., 2024). Patients often report mild physical changes, but symptoms can quickly escalate.

Common signs span a wide spectrum. As outlined by the American Cancer Society (2024), indicators include:

• Itching and facial or neck redness (flushing)
• Skin rashes or hives
• Fever, chills, or sudden, unexplainable anxiety
• Muscle, joint, back, or belly pain
• Gastrointestinal distress like nausea, vomiting, or diarrhea
• Cardiovascular and respiratory shifts such as a fast heartbeat, dizziness, lightheadedness, cough, shortness of breath, or chest discomfort

Severe hypersensitivity or anaphylaxis brings dangerous warning signs. Care teams look out for wheezing, throat or chest tightness, swelling of the face, lips, or tongue, plummeting blood pressure, confusion, and fainting (American Cancer Society, 2024; Cancer Care Ontario, 2019).

Cancer Therapies Most Commonly Associated with Reactions

While any intravenous drug can theoretically provoke an immune response, certain medication classes carry a much higher baseline risk. Taxane chemotherapy drugs—specifically paclitaxel and docetaxel—alongside etoposide and platinum agents like carboplatin, cisplatin, and oxaliplatin, are well-documented culprits (Barroso et al., 2024; American Cancer Society, 2024).

Monoclonal antibodies represent another major category. Agents such as rituximab, cetuximab, trastuzumab, daratumumab, and intravenous amivantamab frequently provoke reactions, often during the first or second administration (Barroso et al., 2024). Immune checkpoint inhibitors like pembrolizumab and nivolumab also carry potential risks, though the exact timing and severity fluctuate based on individual clinical factors (American Cancer Society, 2024).

Immediate Protocols for Managing Infusion Reactions

When an adverse event unfolds, the immediate clinical response is swift. Healthcare providers will pause the infusion to evaluate vital signs, including blood pressure, heart rate, temperature, and oxygen saturation, while keeping the intravenous line open for emergency medications or fluids (Roselló et al., 2017; Cancer Care Ontario, 2019).

Mild to moderate symptoms are frequently treated with antihistamines, corticosteroids, or fever reducers. Once symptoms subside completely, clinical teams may cautiously resume the therapy at a reduced infusion rate under close surveillance, occasionally paired with preventive drugs (Roselló et al., 2017). Conversely, true anaphylaxis demands aggressive intervention. According to the American Cancer Society (2024), Epinephrine (like an epi pen) must be given to treat anaphylaxis, alongside oxygen and supportive hospital care.

Prevention Strategies and Premedication Protocols

Although these events cannot always be avoided, clinicians utilize targeted strategies to minimize their frequency and severity. For high-risk therapies, patients are frequently administered premedications prior to treatment (Roselló et al., 2017; Barroso et al., 2024).

Common preventive medications include:

• Antihistamines such as diphenhydramine (Benadryl) or famotidine (Pepcid)
• Steroids like prednisone or dexamethasone (Decadron)
• Anti-fever drugs such as acetaminophen (Tylenol)

Additional safety measures include administering initial doses at a slower infusion rate and utilizing specialized desensitization protocols—where the drug is given in gradually increasing amounts under strict medical supervision—for patients who require a specific, necessary medication despite a history of severe reactions (Roselló et al., 2017; Barroso et al., 2024).